November 11-13, National Harbor, MD
National Harbor, MD – Nov. 2 2016 – Flagship Biosciences, the leader in tissue image analysis, announced today that they will be presenting new data at the Annual Meeting of the Society for Immunotherapy of Cancer being held November 11-13, with exhibits from Nov. 11-12.
Flagship’s scientists will be presenting two scientific posters detailing the company’s latest developments in immune and tumor cell analysis. We encourage attendees to mark the dates and times on their calendar to see the posters.
Scientific poster details:
- Analytical Validation of Ki67/CD8 Duplex IHC Assay Using Computational Tissue Analysis (cTA™)
- Objective and Consistent Scoring of a PD-L1 Complimentary Diagnostic with Computational Tissue Analysis (cTA™)
The SITC 31st Annual Meeting provides a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy.
Flagship’s scientific collaboration and peer-to-peer partnering with drug developers supports confident decision making for clinical trials and companion diagnostic development, with a focus on biomarker strategy development and patient selection planning for clinical phase immunotherapies. The company’s advanced tissue analysis approach, computational Tissue Analysis (cTA™), gives clients reliable data and a deep understanding of their biological endpoints for efficacy testing, pharmacodynamics, and patient selection strategies.
Flagship’s booth, #127, will be located along the west corridor of the exhibit hall. Attendees are encouraged to visit the booth, relax, recharge, and discuss their clinical immuno-oncology needs with Flagship’s team.
The following link will provide you with a Quick Guide to finding Flagship’s booth in the exhibit hall.
SITC 2016 Quickguide
The Society for Immunotherapy of Cancer (SITC) is a 501(c)(3) non-profit professional society of influential scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.
About Flagship Biosciences
Flagship collaborates with drug developers to confidently define their path to success. By leveraging our unique computational Tissue Analysis (cTA™) and Data-Driven-Decision Support Platform, we provide quantitative and contextual tissue interpretation to make confident decisions and reduce your risk of failure. Our peer-to-peer decision support process ensures that our robust tissue analysis data leads to the direct, confident decisions needed to accelerate drug development. Follow Flagship on Twittter: @FlagshipBio
7575 W. 103rd Ave, Suite 102
Westminster, CO 80021